| Views | |
|---|---|
| Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron | 207 |
| July 2025 | August 2025 | September 2025 | October 2025 | November 2025 | December 2025 | January 2026 | |
|---|---|---|---|---|---|---|---|
| Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron | 3 | 2 | 11 | 27 | 12 | 2 | 65 |
| Views | |
|---|---|
| 2023_Kreye_etal.pdf | 51 |
